Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NASDAQ /
  3. AKTX.NASDAQ

Akari Therapeutics PLC (AKTX NASDAQ) stock market data APIs

$4 -0.25(-5.9%) as of July 26, 2024
Price chart is built with Anychart

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA. The company is headquartered in Boston, Massachusetts.

Akari Therapeutics PLC Financial Data Overview

4.25
4
-
4.4
3.86
1.0775-5.5
45 321 K
11 741 K
0
-0.8275
0.915
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'AKTX',
Type: 'Common Stock',
Name: 'Akari Therapeutics PLC',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG003PMV495',
ISIN: NULL,
CUSIP: NULL,
CIK: NULL,
EmployerIdNumber: '98-1034922',
FiscalYearEnd: 'December',
IPODate: '2015-09-21',
InternationalDomestic: 'Domestic',
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: 'ADR',
IsDelisted: false,
}

Akari Therapeutics PLC Fundamental Data is available in our Financial Data APIs

  • Net Revenue 0
  • EBITDA -18 185 000
  • Earnings Per Share -3.14
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Akari Therapeutics PLC Earnings via APIs

  • Latest Release 2024-05-15
  • EPS/Forecast NaN

Get Akari Therapeutics PLC End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Akari Therapeutics PLC latest news via APIs

Akari Therapeutics Presents Poster on Progress in Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference

BOSTON and LONDON, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases...
  • AKARI THERAPEUTICS PLC
  • HEALTH
  • NASDAQ:AKTX

Akari Therapeutics to Present a Poster on Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference

BOSTON and LONDON, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases...
  • AKARI THERAPEUTICS PLC
  • CALENDAR OF EVENTS
  • NASDAQ:AKTX
Do you have any questions?
support@eodhistoricaldata.com